I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $153.19M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
|
| ||||
Anacor Pharmaceuticals Inc. |
Palo Alto, Calif. |
10/29 |
$7 |
Anacor raised $3M in April in a first round and $4M in October in a second round for a total of $7M; investors in both rounds were Rho Ventures and Aberdare Ventures |
Aptanomics SA |
Lyon, France |
10/28 |
€7 |
Aptanomics raised US$6.9M in a financing with investors CDC Innovation, Bioam, Ventech and AGF Private Equity |
Codexis Inc. |
Redwood City, Calif. |
10/4 |
$25 |
Codexis raised $25M in its first private financing since its establishment as a subsidiary of Maxygen Inc.; CMEA Ventures and Pequot Ventures led the round, which included investments from ChevronTexaco Technology Ventures and Maxygen |
CreAgri Inc. |
Hayward, Calif. |
10/11 |
$8.3 |
CreAgri raised $8.3M in its first round led by Burrill & Company; other investors were POSCO BioVentures, DSM Venturing BV, Foragen Technologies Management LP and Aurora Equity LLC |
EcoBiotics Ltd. |
Brisbane, Australia |
10/30** |
A$3 |
EcoBiotics raised US$1.62 from investors |
Enact Pharma plc |
Salisburg, UK |
10/16** |
£0.4 |
Enact raised US$620,000 in a financing with New Opportunities Investment Trust plc |
Etiologics Ltd. |
Oxford, UK |
10/7 |
£3.5 |
Etiologics raised $5.25M in initial venture capital backing from MVM Ltd. and ABN AMRO Capital |
Kemia Inc. |
San Diego |
10/30 |
$16.5 |
Kemia raised $16.5M in a Series A financing; investors were Forward Ventures, Alta Partners and Texas Pacific Group |
MerLion Pharmaceuticals Pte. Ltd. |
Singapore |
10/30 |
$13 |
MerLion raised $13M in its first round led by Aravis; other investors were BioVeda, EDB BioMedical Sciences Investment Fund, JAFCO Asia Technology, Novartis BioVentures, Temasek Holdings and UOB Hermes Asia Technology |
Neurogenetics Inc. |
La Jolla, Calif. |
10/30 |
$10 |
Neurogenetics raised $10M in a Series B financing; investors were Alta Partners, Advent International, GIMV Venture Capital, Novartis Venture Fund, S.R. One Ltd. and Eisai Co. Ltd. |
Peninsula Pharmaceuticals Inc. |
Fremont, Calif. |
10/28 |
$22.1 |
Peninsula raised $22.1M in a financing led by Domain Associates; other investors were Canaan Partners, A.M. Pappas & Associates, Montreux Equity Partners, Mitsubishi International Corp. and Sears Capital Management Inc. |
Pieris Proteolab AG |
Freising, Germany |
10/31 |
€12 |
Pieris raised US$12M in a Series A financing led by Global Life Science Ventures and Gilde Investment Management BV; other investors were Bay Tech Venture Capital, ABN AMRO Capital, BioM Venture Capital and TransConnect |
Rubicon Genomics Inc. |
Ann Arbor, Mich. |
10/1 |
$3.5 |
Rubicon raised $3.5M in a Series B round led by ARCH Development Partners, with participation from Duchossois TECnology Partners, Sloan Ventures and individual investors |
Sireen AG |
Martinsried, Germany |
10/30 |
€5 |
Sireen raised US$4.9M from a syndicate of investors led by DVC Deutsche Venture Capital and including ABN AMRO Capital |
Sucampo Pharmaceuticals Inc. |
Bethesda, Md. |
10/11 |
$4.5 |
Sucampo raised another $4.5M in a Series A round with a $3M investment from Mizuho Capital Co. Ltd. and a $1.5M investment from Diamond Capital Co. Ltd. |
Xerion Pharmaceuticals Inc. |
Martinsried, Germany |
10/8 |
€12.3 |
Xerion closed its third round of financing, raising US$12M; Heidelberg Innovation and Nextech Ventures led the round; other investors were 3i, IKB Venture Capital and BioM |
|
| ||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $12M | ||||
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
|
| ||||
Applied Molecular Evolution Inc. (AMEV) |
Eli Lilly and Co. |
ND |
Milestone payment |
Applied Molecular received the payment for successfully meeting criteria for improving the potency, affinity and stability of the molecule as specified in the collaboration agreement (10/16) |
ArQule Inc. (ARQL) |
Wyeth |
ND |
Milestone payment |
ArQule received the payment after Wyeth nominated a compound targeted in women's health to its development pipeline (10/7) |
Atrix Laboratories Inc. (ATRX) |
Sanofi-Synthelabo Inc. (France) |
$6 |
Milestone payment |
Atrix received $6M for the introduction of Eligard 22.5 mg to treat advanced prostate cancer (10/15) |
Direvo Biotech AG* (Germany) |
Novozymes A/S (Denmark) |
ND |
Milestone payment |
Direvo received the payment after an achievementin its collaboration to optimize an industrial enzyme for one of Novozymes' core industry segments (10/2) |
ImmunoGen Inc. (IMGN) |
Boehringer Ingelheim International GmbH (Germany) |
ND |
Milestone payment |
ImmunoGen received an undisclosed payment for initiating clinical trials in its collaboration with Boehringer to develop an anticancer agent using DM1 Tumor-Activated Prodrug technology (10/15) |
Maxygen Holdings Ltd. (subsidiary of Maxygen Inc.; MAXY) |
InterMune Inc. |
$1 |
Milestone payment |
Maxygen received the payment for achieving drug performance criteria in its alliance with InterMune to develop a next-generation version of Actimmune that can be taken once weekly rather than three times a week (10/7) |
Nastech Pharmaceutical Co. Inc. (NSTK) |
Pharmacia Corp. |
$1 |
Milestone payment |
Nastech received the payment as part of its collaboration for intranasally administered apomorphine for male and female sexual dysfunction (10/2) |
Targeted Genetics Corp. (TGEN) |
Biogen Inc. |
$4 |
Equity investment |
Targeted Genetics received $4M after issuing 5.8M shares at 69 cents each to Biogen as part of a September 2000 equity purchase commitment in the companies' collaboration to develop up to four gene therapy products (10/8) |
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.